These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 2868819)

  • 21. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
    Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
    Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The genetic control of bufuralol metabolism in man.
    Dayer P; Balant L; Courvoisier F; Kupfer A; Kubli A; Gorgia A; Fabre J
    Eur J Drug Metab Pharmacokinet; 1982; 7(1):73-7. PubMed ID: 6121708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.
    McGourty JC; Silas JH; Fleming JJ; McBurney A; Ward JW
    Clin Pharmacol Ther; 1985 Oct; 38(4):409-13. PubMed ID: 2864157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic characterization of human liver microsomal cytochromes P-450 involved in the oxidation of debrisoquine, bufuralol and the carcinogen 2-acetylaminofluorene.
    McManus ME
    Pharmacol Ther; 1987; 33(1):47-53. PubMed ID: 2888142
    [No Abstract]   [Full Text] [Related]  

  • 27. Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.
    Lewis RV; Ramsay LE; Jackson PR; Yeo WW; Lennard MS; Tucker GT
    Br J Clin Pharmacol; 1991 Apr; 31(4):391-8. PubMed ID: 2049246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
    Boobis AR; Murray S; Hampden CE; Davies DS
    Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers.
    Dayer P; Mérier G; Perrenoud JJ; Marmy A; Leemann T
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S20-4. PubMed ID: 2439813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
    Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
    J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
    Gleiter CH; Aichele G; Nilsson E; Hengen N; Antonin KH; Bieck PR
    Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.
    Lennard MS; Tucker GT; Silas JH; Freestone S; Ramsay LE; Woods HF
    Clin Pharmacol Ther; 1983 Dec; 34(6):732-7. PubMed ID: 6641087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.
    Jonkers RE; Koopmans RP; Portier EJ; van Boxtel CJ
    J Pharmacol Exp Ther; 1991 Mar; 256(3):959-66. PubMed ID: 1848636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta-blockers and debrisoquine metaboliser status.
    Jack DB; Kendall MJ
    Lancet; 1982 Mar; 1(8274):741. PubMed ID: 6122034
    [No Abstract]   [Full Text] [Related]  

  • 37. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.
    Dayer P; Leemann T; Marmy A; Rosenthaler J
    Eur J Clin Pharmacol; 1985; 28(2):149-53. PubMed ID: 2859203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
    Al-Dabbagh SG; Idle JR; Smith RL
    J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
    Lennard MS
    Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.